No Detail Found!

Clinical application of irinotecan combined with first-line chemotherapeutics against pediatric hepatoblastoma with pulmonary metastasis

Author(s)
Huimin Hu Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University,Beijing,China
Weiling Zhang Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University,Beijing,China
Jing Li Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University,Beijing,China
Fan Li Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University,Beijing,China
Yuan Wen Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University,Beijing,China
Yanyan Mei Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University,Beijing,China
Dongsheng Huang Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University,Beijing,China
Abstract
This study aimed to investigate the short-term efficacy and adverse reactions of irinotecan combined with first-line chemotherapeutics for the treatment of pediatric hepatoblastoma with pulmonary metastasis (HB-PM). Forty-one pediatric patients with HB-PM undergoing cisplatin + fluorouracil + vincristine + doxorubicin (C5VD) treatment with bad therapeutic effect or bad response were instead treated with two cycles of an irinotecan protocol (vincristine + irinotecan + cyclophosphamide + cisplatin). The changes in recent alpha-fetoprotein (AFP), efficacy and adverse reactions in these patients were statistically analyzed. Results showed that, the median level of AFP before chemotherapy was 56432 µg/L; however, it was significantly lower (749 µg/L) after two cycles of chemotherapy (rank sum test, P = 0.00). After two cycles of chemotherapy, three patients achieved a complete response and 32 patients achieved a partial response. The recent efficacy cases accounted for 85.36% of patients (35/41). The delayed diarrhea was the most common adverse reaction to irinotecan, with an incidence rate of 58.53% (24/41), which was improved after symptomatic treatment. In conclusion, the protocol of irinotecan combined with first-line chemotherapeutics can be used for the treatment of HB-PM that is not sensitive to the C5VD protocol, with good short-term curative effect and tolerable adverse reactions.
Publication Details
Page(s) 1301-1306
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 35, Issue: 5, Year: 2022

Request the full text from PASTIC

Keywords
Adverse reactions, irinotecan, Alpha-fetoprotein., Hepatoblastoma
0

Citations

0

Downloads

153

Views